Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the stomach. The vast majority of cases arise from the corpus-fundus region. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent. It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.
Biomarker and diagnostic research for gastric neuroendocrine tumor G1 has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and biologic therapy. Pipeline includes 1 PHASE3, 1 NA. Research is primarily sponsored by academic and government institutions.
56 publications have been identified in PubMed for gastric neuroendocrine tumor G1. Research spans Diagnostic / Biomarker (20%), Clinical Trial Publication (20%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 11 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:07 PM UTC
20%
Clinical study results | 11 | 20% |
Research summaries | 9 | 16% |
Patient case studies | 9 | 16% |
Disease patterns and progression | 8 | 14% |
Laboratory research | 7 | 13% |
Other research | 1 | 2% |
Asmar C (2026). [PMID: 41547118](https://pubmed.ncbi.nlm.nih.gov/41547118/). *Cancer epidemiology*. [Clinical Trial Publication]
Belev B (2026). [PMID: 41812599](https://pubmed.ncbi.nlm.nih.gov/41812599/). *Surgical oncology*. [Review / Meta-Analysis]
Hou WH (2026). [PMID: 41566172](https://pubmed.ncbi.nlm.nih.gov/41566172/). *Zhonghua yi xue za zhi*. [Basic Science / Preclinical]
Dell'Unto E (2026). [PMID: 41016874](https://pubmed.ncbi.nlm.nih.gov/41016874/). *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. [Epidemiology / Natural History]
Skill NJ (2026). [PMID: 41499067](https://pubmed.ncbi.nlm.nih.gov/41499067/). *Journal of gastrointestinal cancer*. [Diagnostic / Biomarker]
Kim BJ (2026). [PMID: 41502317](https://pubmed.ncbi.nlm.nih.gov/41502317/). *Journal of gastroenterology and hepatology*. [Epidemiology / Natural History]
Uccella S (2026). [PMID: 41273419](https://pubmed.ncbi.nlm.nih.gov/41273419/). *Virchows Archiv : an international journal of pathology*. [Review / Meta-Analysis]
Ergenç M (2026). [PMID: 41998800](https://pubmed.ncbi.nlm.nih.gov/41998800/). *Cancer Control*. [Diagnostic / Biomarker]
Vyas M (2026). [PMID: 41717808](https://pubmed.ncbi.nlm.nih.gov/41717808/). *The American journal of surgical pathology*. [Case Report / Case Series]
Ohashi T (2026). [PMID: 41697540](https://pubmed.ncbi.nlm.nih.gov/41697540/). *Clinical journal of gastroenterology*. [Diagnostic / Biomarker]
AI-curated news mentioning gastric neuroendocrine tumor G1
Updated Mar 7, 2026
A recent study evaluates surgical paradigms for gastric neuroendocrine tumors, comparing outcomes with adenocarcinoma approaches. This analysis provides insights into treatment strategies for this rare tumor type.
A case study highlights a gastric neuroendocrine tumor exhibiting a unique raspberry-like appearance, potentially linked to acid-suppressive therapy-related gastropathy. This finding may provide insights into the pathology of gastric tumors in patients undergoing long-term acid suppression.